Ashigarakami-gun, Japan

Takeshi Yamaura

USPTO Granted Patents = 1 

Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2018

Loading Chart...
1 patent (USPTO):Explore Patents

Title: **Innovator Takeshi Yamaura: Pioneering Cancer Treatment**

Introduction

Takeshi Yamaura, based in Ashigarakami-gun, Japan, is an accomplished inventor known for his significant contributions to the field of pharmaceutical innovation. With a focus on developing treatments for serious medical conditions, Yamaura's work is particularly notable in the realm of cancer therapies.

Latest Patents

Takeshi Yamaura holds a patent for a pharmaceutical composition aimed at treating FLT3 mutation-positive cancer. This invention includes a mutant FLT3 inhibitor and outlines multiple uses for this composition. The patent discloses a method that involves detecting the presence or absence of an FLT3 mutation to predict therapeutic effects and select suitable subjects for treatment. This innovative pharmaceutical product shows promise in combating cancers associated with this specific genetic mutation.

Career Highlights

Yamaura is currently associated with Fujifilm Corporation, a leading company known for its advanced technology in imaging and information. His role within the organization has allowed him to contribute to groundbreaking advancements in cancer treatment and pharmaceutical research.

Collaborations

Throughout his career, Yamaura has collaborated with esteemed colleagues such as Tomoki Naoe and Hitoshi Kiyoi. Their collective expertise has been vital in developing and refining the therapeutic strategies outlined in his patent.

Conclusion

With a commitment to medical innovation, Takeshi Yamaura exemplifies the pivotal role inventors play in enhancing healthcare solutions. His dedication to advancing cancer treatment through targeted pharmaceutical compositions holds great promise for patients dealing with FLT3 mutation-positive cancers.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…